Company intelligence / Profile preview

ONCOtracker

West Hollywood, California, United States

Ownership: Private
Employees: ~4
Development stage: Other

Overview

ONCOtracker has developed a clinically validated ELISA-based sBCMA blood test used in research and clinical laboratory settings to monitor tumor burden and predict outcomes in multiple myeloma and related B‑cell malignancies; its sBCMA technology is globally licensed to The Binding Site Group for diagnostic development, while ONCOtracker continues to support ongoing clinical research and holds IP on novel myeloma treatment approaches in early clinical trials[1].

Therapeutic areas: OncologyHematology
Modalities: Diagnostic testImmunoassayELISA
Industry: Biotech

Partnerships

The Binding Site Group (exclusive global license and collaboration to develop and commercialize an sBCMA test for multiple myeloma, chronic lymphocytic leukemia and additional conditions)[1].

Beyond the preview

Go deeper on ONCOtracker.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONCOtracker.

Explore the full profile